ARCHIVES

Over Half of ALK-Positive NSCLC Patients Responded To Crizotinib In Colorado Study

This article is from The Cancer Letter archive.

Vol. 33 No. 11 | November 26, 2010

Download PDF Visit The Full Archive

Related Articles

Also NIH unveils Roadmap initiatives, releases four RFAs; Director Zerhouni defends peer review before House, Senate oversight committees, seeks greater authority for trans-NIH initiatives.

October 3, 2003

ACS Urges Bush To Increase NCI Budget.

January 19, 2007

Fidaxomicin for CDI Therapy More Cost-Effective Than Vancomycin, Study Says

September 26, 2014

DCT Board Approves Concepts Of Eight New Biological Response Modifiers Program

July 3, 1981

Komen, ACS Support Payment Off-Protocol; Dilemma for Advocates

April 16, 1999

In Brief: CREG To Be Used In Viral Oncology, Nutrition, Cell Kinetics, Immunology, Rauscher Tells NCAB

April 4, 1975